AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37021342 — intervention group
Group type: EXPERIMENTAL
Intervention: Rise of >5 bpm in weekly average NHR
Number of subjects: 1013
Study 37021397 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab administered intravenously (IV)
Number of subjects: 42
Study 37021397 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab administered subcutaneously (SC)
Number of subjects: 42
Study 37021397 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (both IV and SC)
Number of subjects: 42
Study 37021527 — intervention group
Group type: EXPERIMENTAL
Intervention: Five doses of intrathecal methotrexate (MTX)
Number of subjects: 6716
Study 37021527 — intervention group
Group type: COMPARATOR
Intervention: Three doses of intrathecal methotrexate (MTX)
Number of subjects: 6716
Study 37021546 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol-coated haemostatic patch (patch group)
Number of subjects: 64
Study 37021546 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reinforcement)
Number of subjects: 64
Study 37021629 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Number of subjects: 99
Study 37021629 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 mL 0.9% saline and oral simulation capsule)
Number of subjects: 99
Study 37021692 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual azithromycin distributions targeted to children aged 0-5 years
Number of subjects: 48
Study 37021692 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual azithromycin distributions targeted to households with a child aged 0-5 years with clinically active trachoma
Number of subjects: 48
Study 37021692 — intervention group
Group type: COMPARATOR
Intervention: Continued annual mass azithromycin distributions to the entire community
Number of subjects: 48
Study 37021692 — intervention group
Group type: COMPARATOR
Intervention: Cessation of treatment
Number of subjects: 48
Study 37021699 — intervention group
Group type: EXPERIMENTAL
Intervention: Transportation assistance
Number of subjects: 24
Study 37021699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition supplementation
Number of subjects: 24
Study 37021807 — intervention group
Group type: EXPERIMENTAL
Intervention: 20g/day SQ-LNSs
Number of subjects: 2711
Study 37021952 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective arm examining all consecutive patients referred for echocardiography with suspected or confirmed endocarditis, followed up over 12 months for adverse outcomes.
Number of subjects: 0
Study 37021952 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriateness of requests for first-line echocardiographic imaging in exclusion of endocarditis.
Number of subjects: 0
Study 37021952 — intervention group
Group type: EXPERIMENTAL
Intervention: Role of other imaging modalities in the diagnosis of endocarditis.
Number of subjects: 0
Study 37021952 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of a specialized endocarditis team on outcomes.
Number of subjects: 0
Study 37022378 — intervention group
Group type: EXPERIMENTAL
Intervention: Third-generation cephalosporin
Number of subjects: 599
Study 37022378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 599
Study 37022378 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 599
Study 37022483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation within 2 weeks of registration, followed by follow-up visits every 2 weeks for the first month, then every 4 weeks until week 16.
Number of subjects: 40
Study 37022483 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation
Number of subjects: 40
Study 37022502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Restructuration Treatment Group (CRTG, n=13)
Number of subjects: 27
Study 37022502 — intervention group
Group type: COMPARATOR
Intervention: Non-structured interviews (PIG group, n=14)
Number of subjects: 27
Study 37022569 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab IV administration (0.1 to 24 mg/kg)
Number of subjects: 850
Study 37022569 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab SC administration (1200 and 1800 mg)
Number of subjects: 850
Study 37022569 — intervention group
Group type: EXPERIMENTAL
Intervention: QSS approximation
Number of subjects: 850
Study 37022569 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline M protein as a covariate
Number of subjects: 850
Study 37022679 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal nerve stimulation (THN) activated at month 1
Number of subjects: 138
Study 37022679 — intervention group
Group type: COMPARATOR
Intervention: Control group (THN activated at month 4)
Number of subjects: 138
Study 37022679 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal nerve stimulation (THN)
Number of subjects: 138
Study 37022680 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan
Number of subjects: 328
Study 37022680 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness Walking
Number of subjects: 328
Study 37022680 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 328
Study 37022682 — intervention group
Group type: EXPERIMENTAL
Intervention: Communities That Care (CTC) intervention
Number of subjects: 4407
Study 37022682 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4407
Study 37022682 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC intervention
Number of subjects: 4407
Study 37022687 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 538
Study 37022687 — intervention group
Group type: COMPARATOR
Intervention: TRZ
Number of subjects: 538
Study 37022702 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy (MDT) with intermittent hormone therapy (combined therapy arm; n=43)
Number of subjects: 87
Study 37022702 — intervention group
Group type: COMPARATOR
Intervention: Hormone therapy only (n=44)
Number of subjects: 87
Study 37022706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab (3 mg/kg IV every 2 weeks plus 1 mg/kg IV every 6 weeks)
Number of subjects: 425
Study 37022706 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (3 mg/kg IV every 2 weeks)
Number of subjects: 425
Study 37022717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine solution, 0.1%, applied twice daily for 29 days
Number of subjects: 834
Study 37022717 — intervention group
Group type: COMPARATOR
Intervention: Vehicle, applied twice daily for 29 days
Number of subjects: 834
Study 37022717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine solution, 0.1%
Number of subjects: 834
Study 37022717 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 834
Study 37022774 — intervention group
Group type: EXPERIMENTAL
Intervention: Atellica® IM High-Sensitivity Troponin I (hs-cTnI) assay with a threshold of <10 ng/L
Number of subjects: 1171
Study 37022774 — intervention group
Group type: EXPERIMENTAL
Intervention: Atellica® IM High-Sensitivity Troponin I (hs-cTnI) assay
Number of subjects: 1171
Study 37022784 — intervention group
Group type: EXPERIMENTAL
Intervention: Amivantamab
Number of subjects: 0
Study 37022932 — intervention group
Group type: EXPERIMENTAL
Intervention: Total ankle replacement
Number of subjects: 303
Study 37022932 — intervention group
Group type: COMPARATOR
Intervention: Ankle fusion
Number of subjects: 303
Study 37022932 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-bearing total ankle replacement
Number of subjects: 303
Study 37023031 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesia-centered bundle focused on perioperative lung expansion
Number of subjects: 750
Study 37023031 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 750
Study 37023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional cast (FC)
Number of subjects: 105
Study 37023069 — intervention group
Group type: COMPARATOR
Intervention: Volar-flexion ulnar deviation cast (VFUDC)
Number of subjects: 105
Study 37023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of treatment
Number of subjects: 105
Study 37023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measurement (15D)
Number of subjects: 105
Study 37023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Short version of Disabilities of arm, shoulder and hand score (QuickDASH)
Number of subjects: 105
Study 37023069 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 105
Study 37023284 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportion of network members engaging in regular cannabis and heavy alcohol use
Number of subjects: 0
Study 37023284 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportions of network members engaging in heavy alcohol use, regular cannabis use, or other drug use
Number of subjects: 0
Study 37023284 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher proportions of network members engaging in traditional practices
Number of subjects: 0
Study 37023336 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 64
Study 37023336 — intervention group
Group type: EXPERIMENTAL
Intervention: Hesperidin
Number of subjects: 64
Study 37023336 — intervention group
Group type: COMPARATOR
Intervention: Silver Diamine Fluoride (SDF)
Number of subjects: 64
Study 37023336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 37023374 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritumoral injection of 0.5% lidocaine, 7-10 minutes before surgery
Number of subjects: 1583
Study 37023374 — intervention group
Group type: COMPARATOR
Intervention: Surgery without lidocaine
Number of subjects: 1583
Study 37023398 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary and Alternative Medicine
Number of subjects: 0
Study 37023443 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coach-supported mental health app
Number of subjects: 25
Study 37023451 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg Intrauterine Device
Number of subjects: 0
Study 37023451 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37023455 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 52-mg intrauterine device (IUD)
Number of subjects: 105
Study 37023457 — intervention group
Group type: EXPERIMENTAL
Intervention: Estetrol 15 mg and drospirenone 3 mg (24 hormone and four placebo pills regimen)
Number of subjects: 2837
Study 37023659 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly cash payment of 300 Rand conditional on school enrollment of index young women
Number of subjects: 3568
Study 37023660 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples nutrition
Number of subjects: 960
Study 37023660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers bundled nutrition and parenting
Number of subjects: 960
Study 37023660 — intervention group
Group type: EXPERIMENTAL
Intervention: Couples bundled nutrition and parenting
Number of subjects: 960
Study 37023660 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 960
Study 37023660 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers nutrition
Number of subjects: 960
Study 37023705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 300 mg daily, carboplatin AUC2, paclitaxel 80 mg m-2 days 1, 8, and 15 every 28 days (Arm A)
Number of subjects: 28
Study 37023705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 400 mg daily, carboplatin AUC2 days 1, 8, and 15 every 28 days (Arm B)
Number of subjects: 28
Study 37023705 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib 300 mg 21 days on 7 days off, capecitabine 750 mg m-2, twice a day, 7 days on 7 days off, atezolizumab 840 mg days 1 and 15 every 28 days (Arm C)
Number of subjects: 28
Study 37023789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory split-dose bowel preparation (SDBP)
Number of subjects: 770
Study 37023789 — intervention group
Group type: COMPARATOR
Intervention: Optional split-dose bowel preparation (SDBP)
Number of subjects: 770
Study 37023858 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release buprenorphine
Number of subjects: 13
Study 37023858 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine
Number of subjects: 13
Study 37023945 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid analgesia
Number of subjects: 27
Study 37023987 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy in combination with Durvalumab
Number of subjects: 0
Study 37023987 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37024247 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT (Sleepio)
Number of subjects: 100
Study 37024247 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 100
Study 37024249 — intervention group
Group type: EXPERIMENTAL
Intervention: RMC-035 (1.3 or 0.65 mg/kg intravenous infusion, five doses based on presurgery estimated glomerular filtration rate)
Number of subjects: 268
Study 37024249 — intervention group
Group type: EXPERIMENTAL
Intervention: RMC-035
Number of subjects: 268
Study 37024249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 37024252 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed orthosis
Number of subjects: 20
Study 37024252 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthosis
Number of subjects: 20
Study 37024268 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral oblique (CLO) view at 50°±5°
Number of subjects: 393
Study 37024277 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 764198
Number of subjects: 129
Study 37024277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 37024298 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation attempts (1 to 6 attempts)
Number of subjects: 1983
Study 37024298 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrillation attempts (higher number of attempts)
Number of subjects: 1983
Study 37024382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation protocols for children with DKA
Number of subjects: 753
Study 37024420 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VMP (Daratumumab + Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Number of subjects: 220
Study 37024420 — intervention group
Group type: COMPARATOR
Intervention: VMP (Bortezomib 1.3 mg/m² + Melphalan + Prednisone)
Number of subjects: 220
Study 37024420 — intervention group
Group type: EXPERIMENTAL
Intervention: D-VMP
Number of subjects: 220
Study 37024420 — intervention group
Group type: COMPARATOR
Intervention: VMP
Number of subjects: 220
Study 37024478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Number of subjects: 157
Study 37024478 — intervention group
Group type: COMPARATOR
Intervention: Delayed or missed intravitreal anti-VEGF injections (IVI) during COVID-19 lockdown
Number of subjects: 157
Study 37024506 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the PBRN
Number of subjects: 152
Study 37024506 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 40 years or older
Number of subjects: 152
Study 37024506 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate clinic size
Number of subjects: 152
Study 37024506 — intervention group
Group type: EXPERIMENTAL
Intervention: Large clinic size
Number of subjects: 152
Study 37024520 — intervention group
Group type: EXPERIMENTAL
Intervention: WVT078 (anti-BCMA× anti-CD3 bispecific antibody) administered intravenously once weekly at doses of 48-250 µg/kg (n=26)
Number of subjects: 33
Study 37024520 — intervention group
Group type: EXPERIMENTAL
Intervention: WVT078 (anti-BCMA× anti-CD3 bispecific antibody)
Number of subjects: 33
Study 37024596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent fasting plus early time-restricted eating (iTRE)
Number of subjects: 209
Study 37024596 — intervention group
Group type: COMPARATOR
Intervention: Calorie restriction (CR)
Number of subjects: 209
Study 37024634 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Our Vows video intervention
Number of subjects: 580
Study 37024811 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological substudy with scheduled blood samples until 12 months after LT
Number of subjects: 500
Study 37024811 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological substudy using nationwide hospital records
Number of subjects: 500
Study 37024811 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential proof-of-concept for adoptive T cell therapy against CMV and VZV
Number of subjects: 500
Study 37024830 — intervention group
Group type: EXPERIMENTAL
Intervention: Early integrated palliative care
Number of subjects: 21
Study 37024830 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 21
Study 37024868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort A (15 NF135-infected mosquito bites under mefloquine prophylaxis)
Number of subjects: 40
Study 37024868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort B (5 NF135-infected mosquito bites and presumptive treatment with artemether/lumefantrine)
Number of subjects: 40
Study 37024906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 76
Study 37024906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 37024945 — intervention group
Group type: EXPERIMENTAL
Intervention: Audit and feedback
Number of subjects: 335
Study 37024945 — intervention group
Group type: EXPERIMENTAL
Intervention: Active learning
Number of subjects: 335
Study 37024948 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs (CM and EM)
Number of subjects: 200
Study 37024948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic migraine (CM)
Number of subjects: 200
Study 37024948 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus accumbens (NAC) iron volume
Number of subjects: 200
Study 37024948 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deposition in NAC
Number of subjects: 200
Study 37024948 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 200
Study 37024961 — intervention group
Group type: EXPERIMENTAL
Intervention: ART readiness tool (27-item questionnaire)
Number of subjects: 454
Study 37024966 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed fluid therapy using balanced crystalloids
Number of subjects: 66
Study 37025023 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Number of subjects: 3493
Study 37025023 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg
Number of subjects: 3493
Study 37025083 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 3581
Study 37025083 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 3581
Study 37025256 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine plus oral antidepressant (AD)
Number of subjects: 252
Study 37025256 — intervention group
Group type: COMPARATOR
Intervention: AD plus placebo
Number of subjects: 252
Study 37025348 — intervention group
Group type: EXPERIMENTAL
Intervention: Skills Program for Awareness, Connectedness, and Empowerment (SPACE)
Number of subjects: 0
Study 37025394 — intervention group
Group type: EXPERIMENTAL
Intervention: Small increase in serum creatinine (Scr) within 48 hours of hospitalization
Number of subjects: 19424
Study 37025394 — intervention group
Group type: COMPARATOR
Intervention: Normal serum creatinine at hospitalization
Number of subjects: 19424
Study 37025594 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking football (WF) program plus usual care
Number of subjects: 50
Study 37025594 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking football (WF) program
Number of subjects: 50
Study 37025684 — intervention group
Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitor (ICM)
Number of subjects: 2
Study 37025684 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight unmatched patients
Number of subjects: 2
Study 37025684 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients
Number of subjects: 2
Study 37025758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg or 480 mg IV) administered for up to 2 years until progression, combined with SRS (15-21 Gy) delivered within 14 days after the first dose of nivolumab.
Number of subjects: 26
Study 37025758 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS (15-21 Gy) to all un-irradiated BM delivered within 14 days after the first dose of nivolumab.
Number of subjects: 26
Study 37025758 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab and SRS combination treatment.
Number of subjects: 26
Study 37026030 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqua polo intervention (20 week programme, 1 session per week, supervised by professional water-polo coaches)
Number of subjects: 24
Study 37026112 — intervention group
Group type: EXPERIMENTAL
Intervention: dupilumab
Number of subjects: 131
Study 37026112 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 131
Study 37026184 — intervention group
Group type: EXPERIMENTAL
Intervention: Room light supplemented with a light emitting diode task lamp (~250 melanopic EDI lux, 210 lux)
Number of subjects: 16
Study 37026184 — intervention group
Group type: COMPARATOR
Intervention: Ambient fluorescent room light (~30 melanopic EDI lux, 50 lux)
Number of subjects: 16
Study 37026184 — intervention group
Group type: EXPERIMENTAL
Intervention: Room light supplemented with a light emitting diode task lamp
Number of subjects: 16
Study 37026184 — intervention group
Group type: COMPARATOR
Intervention: Ambient fluorescent room light
Number of subjects: 16
Study 37026185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention (A Matter of Balance - Netherlands)
Number of subjects: 0
Study 37026185 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37026366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×10
Number of subjects: 0
Study 37026453 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed aerobic and resistance exercise during neoadjuvant therapy (Arm B)
Number of subjects: 151
Study 37026453 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (Arm A)
Number of subjects: 151
Study 37026453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms combined
Number of subjects: 151